Merrimack Pharmaceuticals Inc  

(Public, NASDAQ:MACK)   Watch this stock  
Find more results for MACK
9.76
+0.23 (2.41%)
After Hours: 9.86 +0.10 (1.02%)
Nov 26, 7:21PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.41 - 9.82
52 week 3.33 - 9.82
Open 9.50
Vol / Avg. 1.85M/2.11M
Mkt cap 1.00B
P/E     -
Div/yield     -
EPS -1.03
Shares 105.88M
Beta     -
Inst. own 52%
Dec 18, 2014
Merrimack Pharmaceuticals Inc Analyst Day Add to calendar
Dec 10, 2014
Merrimack Pharmaceuticals Inc at Oppenheimer Healthcare Conference - 3:20PM EST - Add to calendar
Nov 24, 2014
Merrimack Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
Nov 20, 2014
Merrimack Pharmaceuticals Inc at Jefferies Global Healthcare Conference - London
Nov 10, 2014
Q3 2014 Merrimack Pharmaceuticals Inc Earnings Call
Nov 10, 2014
Q3 2014 Merrimack Pharmaceuticals Inc Earnings Release
Sep 24, 2014
Merrimack Pharmaceuticals Inc Conference Call to Discuss its Agreement with Baxter International Inc to Develop and Commercialize Novel Cancer Compound
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -100.13% -273.48%
Operating margin -84.73% -252.25%
EBITD margin - -246.83%
Return on average assets -70.64% -76.56%
Return on average equity - -
Employees 254 -
CDP Score - -

Address

Suite B7201, One Kendall Square
CAMBRIDGE, MA 2139
United States - Map
+1-617-4411000 (Phone)
+1-617-4911386 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. The Company�s Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.

Officers and directors

Gary L. Crocker Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Robert J. Mulroy President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
William A. Sullivan Chief Financial Officer, Treasurer
Age: 42
Bio & Compensation  - Reuters
Ulrik B. Nielsen Ph.D. Chief Scientific Officer, Senior Vice President
Age: 41
Bio & Compensation  - Reuters
Fazal R. Khan Ph.D. Senior Vice President - Manufacturing
Age: 64
Bio & Compensation  - Reuters
William M. McClements Senior Vice President - Corporate Operations
Age: 50
Bio & Compensation  - Reuters
Edward J. Stewart Senior Vice President and President, Merrimack Healthcare Solutions
Age: 43
Bio & Compensation  - Reuters
John Mendelsohn M.D. Director
Age: 77
Bio & Compensation  - Reuters
James H. Quigley Director
Age: 62
Bio & Compensation  - Reuters
James van B. Dresser Independent Director
Age: 72
Bio & Compensation  - Reuters